Yuna Chai
Zhengzhou, China
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 9 publications
Tongxie Yaofang ameliorates IBS-D by targeting the gut microbiota-derived tryptophan metabolites and AhR signaling axis.
Journal: Frontiers in microbiology
Published: January 13, 2026
Inhibition of RAC1 activator DOCK2 ameliorates cholestatic liver injury via regulating macrophage polarisation and hepatic stellate cell activation.
Journal: Biology direct
Published: November 29, 2024
Overexpression of miR-506-3p reversed doxorubicin resistance in drug-resistant osteosarcoma cells.
Journal: Frontiers in pharmacology
Published: September 28, 2023
Integrated omics analysis reveals the epigenetic mechanism of visceral hypersensitivity in IBS-D.
Journal: Frontiers in pharmacology
Published: October 06, 2022
Study on the mechanism of Danshen-Guizhi drug pair in the treatment of ovarian cancer based on network pharmacology and in vitro experiment.
Journal: PeerJ
Published: October 08, 2021
MiRNA-29a modulates visceral hyperalgesia in irritable bowel syndrome by targeting HTR7.
Journal: Biochemical and biophysical research communications
Published: February 21, 2019
Inhibition of miRNA-29a regulates intestinal barrier function in diarrhea-predominant irritable bowel syndrome by upregulating ZO-1 and CLDN1.
Journal: Experimental and therapeutic medicine
Published: October 24, 2018
Role of stem cell growth factor/c-Kit in the pathogenesis of irritable bowel syndrome.
Journal: Experimental and therapeutic medicine
Published: November 26, 2015
Showing 1-9 of 9
Last Updated: 09/26/2026